iBio
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
11750 Sorrento Valley Rd Ste 200, San Di...Phone Number
(979) 446-0027Website
www.ibioinc.comRevenue
<$5 MillionStock Symbol
IBIOIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About iBio
iBio develops next-generation cardiometabolic and obesity therapeutics designed to promote higher-quality weight loss by preserving and building muscle, improving metabolic function, and supporting long-term treatment through more convenient dosing and enhanced tolerability, while complementing existing therapies. The company also advances a preclinical immuno-oncology pipeline targeting hard-to-treat solid tumors, including those in the breast, lung, and colorectal regions, as well as pancreatic cancer and glioblastoma. Its work is powered by a machine-learningdriven antibody discovery platform that provides core services such as precision epitope engineering, access to a proprietary fully human antibody library, antibody optimization through its StableHu technology, next-generation bispecific design via its EngageTx T-cell engager panel, and enhanced safety and developability through its ShieldTx masking system. The company is led by Martin Brenner, DVM, Ph.D., Chief Executive OfficeRead more
iBio Org Chart
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is iBio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if iBio had a recent Job posting/layoffs
Product Launch: Get notified when iBio launches new products
iBio, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at iBio
Earning: See what the market has to say on iBio recently announced quarterly report
Funding: Get notified immidiatlly once iBio has new funding data
Check out if iBio is spiking on competitors!
Check if iBio has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined iBio as Masked Content
Find more new buyers
Compare Similar Companies to iBio
Compare insights from companies similar to iBio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
iBio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
iBio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about iBio.
iBio financials insights
Gather financial insights about iBio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$350K
2025
Other Financing Round
$6.2M
iBio Tech Stack
A closer look at the technologies used by iBio
See more technologies
Most Recent Scoops
Earnings
Earnings, Finance
New Hire
Executive Move
Executive Moves, New Hire
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Legal Affairs, Stake & Stock Ownership, Finance
Event
Events, Engineering, Sales, Bioengineering, Laboratory Operations, Pharmaceuticals, Field /Outside Sales, Clinical Operations, Field Marketing, Operations
iBio News & Media
iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced its financial results for the fiscal year ended June 30, 2026, and provided a corporate update on its progress.Lynx1 Capital Management (IBIO) corrects 5.4% iBio stake including 2.8M warrant shares
Lynx1 Capital Management and Weston Nichols report 5.4% beneficial ownership in iBio, including 2,807,016 shares issuable from Series F warrants subject to a 9.99% blocker.iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer
SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced the appointment of Molly Carr, M.D., as Chief Medical Officer, further strengthening its executive leadership as the company advances its clinical-stage cardiometabolic pipeline. An experienced physician with over 30 years of clinical, academic and biopharmaceutical experienceiBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study
Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding iBio
Sign Up For FreeTo access detailed company insights
iBio develops next-generation cardiometabolic and obesity therapeutics designed to promote higher-quality weight loss by preserving and building muscle, improving metabolic function, and supporting long-term treatment through more convenient dosing and enhanced tolerability, while complementing existing therapies. The company also advances a precli... Read More
